Intrinsiqq

Genovis AB (GENO.XSTO) Quality Score

GENO.XSTO
Quality53

Growth is the primary weakness (avg 35/100). Business quality is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
64.7x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
60/100
25.2x

25–30x, paying up for cash generation

Revenue Growth
70/100
7.3%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
0/100
-2.3%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
60/100
1.6%

Mild dilution under 2%

Margin Trend
90/100
+1.3pp

Expanded 1–3pp, steady progress

Capital Structure
100/100
-kr 90M

Net cash position, no leverage concern

2022
kr 73M
kr 7M
2023
kr 123M
kr 79M
2024
kr 169M
kr 77M
2025
kr 163M
kr 73M
Return on Capital
0/100
7.5%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Genovis AB (GENO.XSTO) quality: score, margins and returns

Genovis AB (GENO.XSTO) scores 53/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 14.8% operating margins and 7.5% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Genovis AB (GENO.XSTO) a high-quality business?+

Genovis AB scores 53 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 14.8% operating margin and a 7.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Genovis AB's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from GENO.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Genovis AB scores well and where it falls behind.

What is Genovis AB's return on invested capital (ROIC)?+

Genovis AB earns about 7.5% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to GENO.XSTO's margins and growth on this scorecard to judge durability.

How profitable is Genovis AB?+

Genovis AB runs an operating margin of about 14.8% and a net margin of about 15.1%. Revenue has grown at roughly 8.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on GENO.XSTO: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Biotechnology

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.